Gonadorelin

Gonadorelin is a synthetic copy of the body's own gonadotropin-releasing hormone (GnRH), the ten-amino-acid brain peptide first sequenced in 1967 ²³. In the body, GnRH is released from the hypothalamus in short bursts; each burst tells the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), the two signals that control ovulation, sperm production, and sex-hormone output ²⁴.

That pulse pattern is the key to how the drug behaves. Delivered briefly, gonadorelin stimulates the reproductive axis. Delivered continuously, the same receptor desensitizes and stops responding, the trick exploited by long-acting GnRH-suppressing cancer drugs ²³.

Gonadorelin is studied in three main settings: as a 100 µg intravenous challenge to test pituitary function and diagnose central precocious puberty (CPP), which is early-onset puberty driven by the brain ¹; as low-dose pump delivery that restores fertility in men and women with hypogonadotropic hypogonadism, a condition in which the brain stops signalling the gonads ⁸; and in veterinary medicine to synchronize ovulation in cattle ¹³.

Commercial forms include gonadorelin acetate for human diagnostic and fertility use, and gonadorelin hydrochloride products such as Factrel for animals ¹³. It is not the same drug as long-acting GnRH analogues like triptorelin or leuprolide, which are chemically modified to persist and suppress the axis ²².

Gonadorelin works by binding the type-I GnRH receptor (GnRHR), a G protein-coupled receptor on the surface of pituitary gonadotroph cells ²⁴. Activation produces two outputs. First, cells release stored LH quickly, with a smaller FSH response; after an intravenous dose in girls, the LH peak arrives at 30-60 minutes ⁴. Second, receptor signalling drives new gonadotropin synthesis, an effect demonstrated in pituitary cell models ²⁶.

The receptor does not distinguish a single pulse from a continuous stream of drug. A pulse produces one LH spike; a continuous infusion desensitizes the receptor so the pituitary stops responding. That desensitization is exactly how long-acting GnRH agonist drugs achieve medical castration in prostate cancer, after an initial testosterone flare ²². Native gonadorelin's rapid breakdown means each injection behaves as a discrete pulse rather than a continuous exposure, which is why it can stimulate the axis where lasting analogues eventually suppress it ²².

Upstream of the pituitary, kisspeptin neurons in the brain's arcuate nucleus are the main excitatory drive onto the GnRH system, and metabolism tunes that drive. In animal models, the gut-hormone-related peptide LEAP2 raises kisspeptin signalling and LH secretion ²⁹, while fasting and undernutrition suppress the axis through a specialized set of kisspeptin-containing neurons ³⁶. This is the circuit through which energy balance, obesity, and chronic disease disturb reproduction.

Diagnostic LH release. A 100 µg intravenous dose reliably provokes an LH surge. A peak LH of 4.7 IU/L or higher identified central precocious puberty with 100% sensitivity and 87% specificity in a cohort of 341 girls ². The response runs lower in heavier girls (median peak 6.2 mIU/mL in obese versus 9.1 in normal weight), so body weight affects interpretation ⁶.

Spermatogenesis in hypogonadal men. In 28 men with congenital hypogonadotropic hypogonadism and no sperm, pump-delivered gonadorelin produced sperm at a median of 6 months versus 14 months for hCG/HMG injections, with 90% reaching sperm output within 24 months ⁸. One man treated after brain surgery normalized testosterone within 6 months of 16 µg pulses every 120 minutes and later fathered children without further treatment ⁹.

Ovulation induction in women. Three months of pulsatile delivery restored ovulation in all 41 women with functional hypothalamic amenorrhea, producing a single dominant follicle per cycle regardless of polycystic ovarian shape ¹¹.

Bone and metabolic changes. Six months of pulsatile therapy in 22 young hypogonadal men increased lumbar spine, femoral neck, and total-hip bone mineral density, and reduced fasting insulin and insulin resistance ¹⁰.

Veterinary fertility. In a 505-cow ultrasound subset, 200 µg intramuscular gonadorelin raised ovulation to 83% versus 71% at 100 µg, while in the full 6,621-cow cohort pregnancy per artificial insemination was higher with 200 µg (51.8% vs 48.6%) ¹³. In estrous cats, a single 50 µg dose induced ovulation in 84% ¹⁷.

Exploratory. In a mouse model of intestinal tumors, repeated gonadorelin injections reduced colon tumor count by roughly 75%, a chemoprevention angle with no human evidence yet ²¹.

Diagnostic stimulation test. The reference-standard protocol is a single 100 µg intravenous bolus with LH sampled at baseline and at 30, 45, and 60 minutes ¹. A peak LH of roughly 4.7-5 IU/L is the usual diagnostic threshold in girls ². When gonadorelin has been in short supply, subcutaneous triptorelin is a validated substitute, though its LH peak arrives later (around 120-180 minutes), so gonadorelin's cutoffs do not transfer between the two ³.

Pulsatile pump therapy for hypogonadotropic hypogonadism. Pump protocols deliver small subcutaneous pulses continuously to imitate the brain's own rhythm. A documented starting protocol is 16 µg every 120 minutes, within a community-practice range of 5-20 µg per pulse at 90- to 120-minute intervals ⁸. Treatment is endpoint-driven rather than calendar-driven: spermatogenesis typically appears around month 6 in men and reaches about 90% by 24 months ⁸.

Pulsatile ovulation induction. In women with functional hypothalamic amenorrhea, three months of pulsatile delivery restored single-follicle ovulation in all 41 women studied, which keeps multiple-pregnancy risk low ¹¹.

Veterinary and community patterns. Cattle protocols use 100-200 µg intramuscularly, with 200 µg preferred for mature cows ¹³. Community protocols sometimes use 50-100 µg subcutaneous or intramuscular doses once or twice daily in short courses, a pattern with no controlled human outcome data.

Gonadorelin ships as a lyophilized (freeze-dried) powder that is mixed with diluent before use. Bacteriostatic water containing 0.9% benzyl alcohol is the standard diluent in community practice, and the peptide itself is freely water-soluble. The diluent is injected slowly against the vial wall and the vial swirled gently rather than shaken. When sterility is uncertain, the solution can be passed through a 0.22 µm syringe filter, a practitioner-consensus step.

Storage differs before and after mixing. The dry powder is best kept frozen at -20°C for long-term storage, or refrigerated at 2-8°C for shorter periods, and kept dry and protected from light. Once mixed, the solution belongs in the refrigerator at 2-8°C and should not be frozen; freeze-thaw cycles accelerate breakdown.

Stability is this peptide's weak point. Gonadorelin degrades and epimerizes (changes shape at specific amino acids) in aqueous solution, with the kinetics characterized in laboratory studies ¹⁹. Community guidance is to use refrigerated reconstituted solution within 14-30 days and discard anything cloudy or containing particles. Engineered slow-release formulations exist in the research pipeline, including a zinc-triggered depot that releases continuously for 14 days in vitro ¹⁸, but these are not the standard vial.

The interactive calculator below handles the dilution math for any vial size, diluent volume, and target dose.

There are no formal drug-interaction trials for gonadorelin itself; the evidence comes from assisted reproduction, oncology, and pediatric protocols involving the same receptor family ²².

Gonadotropins (hCG, HMG). The clearest comparator data: in men with congenital hypogonadotropic hypogonadism, pulsatile gonadorelin produced sperm earlier than cyclical hCG/HMG (median 6 versus 14 months) with fewer androgenic side effects ⁸. In IVF antagonist cycles, GnRH-agonist triggers are used in place of, or alongside, low-dose hCG to prevent ovarian hyperstimulation ⁴⁰.

GnRH antagonists. Drugs like cetrorelix, ganirelix, and relugolix occupy the same pituitary receptor, so concurrent gonadorelin is pharmacologically wasted. Sequential use, by contrast, is deliberate and standard in assisted reproduction ⁴⁰.

Sex steroids. Adding back estrogen or progestin prevents bone loss during long-term GnRH-suppression therapy ⁴³. Exogenous testosterone or hormonal contraceptives suppress the axis through negative feedback and blunt stimulation-test results, a theoretical effect to account for when interpreting tests.

Antiandrogens. For prostate cancer, covering the flare that follows a GnRH-agonist start with an antiandrogen is standard combined androgen blockade ²².

Pharmacogenetics. The FSHB-211 G>T genotype changes the response to stimulation: T-allele carriers show a smaller FSH rise and a larger LH rise, which matters for diagnostic interpretation ⁷.

Supplements. Zinc coordinates with a stabilized gonadorelin derivative in the laboratory, but oral zinc has no documented clinical interaction ¹⁸. Taurine partially restored GnRH/LH/FSH output in heat-stressed mice; human data are absent ⁴⁹.

Gonadorelin is unusual among GnRH-family drugs because short pulses stimulate the axis while continuous exposure suppresses it ²³. Cycling logic follows from that.

Receptor desensitization is the central risk. Continuous, non-pulsatile exposure downregulates pituitary GnRH receptors, the deliberate mechanism of depot agonists used for prostate cancer ²². Each gonadorelin bolus acts as a discrete pulse because the molecule clears in minutes, but overly frequent dosing risks the same desensitization.

On and off periods in practice. Diagnostic testing is single-dose by design ¹. Pump therapy has no formal off-cycle: treatment continues until the endpoint (normalized testosterone, sperm in the ejaculate, or bone and metabolic improvement) is reached, after which the axis is reassessed off therapy. One patient maintained gonadal function and conceived naturally years after a 6-month course ⁹. Community practice commonly runs bolus courses of 8 weeks on followed by 4 weeks off with retesting, to evaluate whether the axis supports independent function between courses.

Response attenuation versus tolerance. A weakening response can be test artifact: higher body weight blunts stimulated LH peaks independent of any tolerance effect ⁶. Diminishing testosterone on an unchanged dose pattern, by contrast, suggests receptor downregulation from excessive exposure frequency and prompts a washout rather than a dose increase in community practice.

No long-acting depot of native gonadorelin exists; depot suppression belongs to the modified analogues ⁶⁰.

Gonadorelin appears in combinations mostly through its clinical family.

With hCG. Dual-trigger protocols in IVF combine a GnRH-agonist trigger with low-dose hCG to support the luteal phase in high responders ⁴². Community protocols also pair gonadorelin with testosterone during therapy to keep the pituitary axis active while exogenous testosterone suppresses it; each pulse produces a short-lived LH transient, and no controlled outcome data exist for that pattern.

With kisspeptin-10. Kisspeptin drives GnRH neurons upstream and has been studied as a diagnostic that spares the GnRH test, using the kisspeptin-10-to-basal-LH ratio ⁵². Co-administration with gonadorelin is unstudied; the two act on different receptors in the same circuit, so synergy is plausible but untested.

With HMG or hCG in male hypogonadotropic hypogonadism. The landmark comparison showed pulsatile gonadorelin reaches sperm output earlier than cyclical hCG/HMG, so these are studied as alternatives rather than partners in that indication ⁸.

With growth hormone. GnRH analogues plus growth hormone, with or without aromatase inhibitors, have been evaluated for short stature in adolescent boys with advanced bone age in a network meta-analysis; the specific conclusion that no antagonism occurs cannot be verified from the available title-only record ⁵⁰.

What opposes it. GnRH antagonists (cetrorelix, relugolix) block the same receptor and would cancel a gonadorelin dose ²³, and anti-GnRH immunocastration vaccines neutralize the peptide itself ⁶².

In the United States, gonadorelin acetate is a marketed prescription diagnostic and fertility agent, used in the GnRH stimulation test codified by the Endocrine Society guideline for central precocious puberty ¹. Veterinary gonadorelin hydrochloride products, such as Factrel, are registered injectables deployed in large dairy timed-AI programs, including randomized field trials with thousands of cows ¹³. Gonadorelin is not a controlled substance and is not an anabolic steroid.

Availability has been fragile: several endocrine centers report that native gonadorelin for stimulation testing is expensive, intermittently unavailable, or in shortage, which has driven substitution with subcutaneous triptorelin in both girls and boys ³.

For athletes, gonadorelin sits on the WADA Prohibited List within class S2 (peptide hormones and releasing factors) as a releasing factor for LH, prohibited at all times in male athletes; national anti-doping bodies apply the same categorization. Because the peptide clears quickly, enforcement leans on downstream gonadotropin and testosterone profiles rather than direct detection.

Internationally, Japan's prescribing is dominated by long-acting GnRH depot drugs, with pulsatile gonadorelin used alongside them ⁹. Several countries have restricted GnRH-analogue therapy in gender-diverse adolescents, a regulatory trend that touches the drug class without targeting gonadorelin itself ⁵⁹.

The side-effect pattern follows from the pharmacology: a single bolus produces a transient hormone surge, and transient effects come with it. Flushing, headache, and brief pelvic or testicular discomfort around the induced LH surge are common and self-limiting within hours.

Hypersensitivity. Anaphylaxis is the serious event to know about. One report describes an 8-year-old girl who had been receiving triptorelin uneventfully for 6 months when she lost consciousness with seizures within 3 minutes of an intravenous gonadorelin dose and recovered with epinephrine and supportive care; whether triptorelin would be tolerated after a gonadorelin anaphylactic reaction is unestablished ¹². A separate case documented immunoglobulin-mediated hypersensitivity during long-term treatment with gonadorelin hydrochloride ³⁸. First intravenous doses are therefore given where resuscitation is available ¹².

Pump therapy. Continuous subcutaneous pump treatment is generally well tolerated; the dominant complaint is infusion-site redness and hardening ⁸. Compared with cyclical hCG/HMG, pulsatile gonadorelin produced less acne and breast tenderness and steadier testosterone ⁸. In women, pulsatile induction produces a single follicle per cycle, keeping multiple-pregnancy and ovarian hyperstimulation risk low ¹¹.

Bone effects. Unlike chronic depot agonists, which can reduce bone density, six months of pulsatile therapy increased spine and hip bone density in hypogonadal men ¹⁰.

Do not confuse with long-acting analogues. Hot flushes, fatigue, and sexual dysfunction are class effects of continuous GnRH-agonist therapy for prostate cancer and do not describe short-acting gonadorelin use ²². One case of psychosis occurred during gonadorelin agonist therapy, an event tied to the long-acting analogues rather than the native peptide ³⁹.

Open questions. Rates of allergic sensitization with repeated long-term use, cross-reactivity between gonadorelin and depot analogues, pregnancy-exposure outcomes, and formal drug-interaction data all remain unestablished ⁷.